Groundbreaking Discovery May Lead to Stronger AntibioticsOctober 02, 2008The last decade has seen a dramatic decline in the effectiveness of antibiotics, resulting in a mounting public health crisis across the world. A new breakthrough by University of Virginia researchers provides physicians and patients a potential new approach toward the creation of less resistant and more effective antibiotics. "As bacteria become more resistant to our current classes of antibiotics, there also has been a general lack of new targets for developing novel antibiotics," says John H. Bushweller, Ph.D., who led a new study appearing in the September 26, 2008, issue of Molecular Cell. "This is a dangerous situation, but our discovery provides a starting point for a completely novel class of antibiotics, acting via a different mechanism." What Dr. Bushweller, professor of molecular physiology and biological physics, and fellow researchers at the UVA Health System and Harvard Medical School have determined is the structure of a particular integral membrane enzyme, called DsbB - one of the many proteins that reside in cell membranes. These so-called integral membrane proteins are important, because they account for roughly one-third of any genome in the human body and are the targets of more than half of all currently used drugs. Until now, scientists have been unable to acquire much structural information about these types of proteins; yet determining a protein's structure is vital in order to understand how it functions and how it can potentially operate as a drug target. The study led by Dr. Bushweller represents the first time scientists have cracked the code required to solve a certain class of membrane protein structure by using nuclear magnetic resonance (NMR) spectroscopy, the preeminent technique for determining the structure of organic compounds. This novel NMR approach now gives the scientific community a brand new platform for attempting to determine structures of other important membrane proteins. "What this means is that not only did we establish NMR spectroscopy as a potent tool for the characterization of the structure, dynamics and function of integral membrane proteins, but we also discovered that the DsbB enzyme is an exciting potential new target agent for the creation of novel antibiotics," says Dr. Bushweller. "This could give us the roadmap to an entirely new class of antibiotics." University of Virginia |
|||||||||||||||||||||
| Related Antibiotics Current Events and Antibiotics News Articles New study finds MRSA on the rise in hospital outpatients The community-associated strain of the deadly superbug MRSA-an infection-causing bacteria resistant to most common antibiotics-poses a far greater health threat than previously known and is making its way into hospitals, according to a study in the December issue of Emerging Infectious Diseases. A Second Skin Despite advances in treatment regimens and the best efforts of nurses and doctors, about 70% of all people with severe burns die from related infections. Study reveals why certain drug combinations backfire Combination drug therapy has become a staple for treating many infections. For instance, doctors treat extensively drug resistant forms of tuberculosis with one drug that breaks down the pathogen's protective barriers and opens the door for another to deliver the deathblow. New imagining technique could lead to better antibiotics and cancer drugs A recently devised method of imaging the chemical communication and warfare between microorganisms could lead to new antibiotics, antifungal, antiviral and anti-cancer drugs, said a Texas AgriLife Research scientist. UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin Researchers from the UCLA Henry Samueli School of Engineering and Applied Science have for the first time successfully reconstituted in the laboratory the enzyme responsible for producing the blockbuster cholesterol-lowering drug lovastatin. Progress made on group B streptococcus vaccine Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, have completed a Phase II clinical study that indicates a vaccine to prevent Group B Streptococcus (GBS) infection is possible. Henry Ford Hospital study: A MRSA strain linked to high death rates A strain of MRSA that causes bloodstream infections is five times more lethal than other strains and has shown to have some resistance to the potent antibiotic drug vancomycin used to treat MRSA, according to a Henry Ford Hospital study. Bacteria 'launch a shield' to resist attack Researchers from the University of Copenhagen and the Technical University of Denmark along with other collaborators in Denmark and the US found that the bacterium Pseudomonas aeruginosa can 'switch on' production of molecules that kill white blood cells - preventing the bacteria being eliminated by the body's immune system. Pumpkin skin may scare away germs The skin of that pumpkin you carve into a Jack-o'-Lantern to scare away ghosts and goblins on Halloween contains a substance that could put a scare into microbes that cause millions of cases of yeast infections in adults and infants each year. Deadly stomach infection rising in community settings, Mayo Clinic study finds Mayo Clinic researchers have found that a sometimes deadly stomach bug, Clostridium difficile is on the rise in outpatient settings. More Antibiotics Current Events and Antibiotics News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||